Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ProMIS Neurosciences (PMN)
Maxim Group analyst Jason McCarthy maintained a Buy rating on ProMIS Neurosciences yesterday and set a price target of $35.00. The company’s shares closed last Friday at $10.39.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.3% and a 31.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, SELLAS Life Sciences Group, and OS Therapies Incorporated.
Currently, the analyst consensus on ProMIS Neurosciences is a Moderate Buy with an average price target of $35.00.
